Folate and vascular disease: Epidemiological perspective

Folate in Health and Disease, Second Edition

Volumn , Issue , 2009, Pages 263-290

  Kalin, Sari R ^a   Rimm, Eric B ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860282551     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (90)

1. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-28.
2. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007; 86:1563S-68.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57.
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288:2015-22.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
6. Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: Biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004; 148:34-40.
7. Homocysteine Lowering Trialists’ Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82:806-12.
8. FDA. Food labeling: Health claims and label statement: Folic acid and neural tube defects. Fed Reg 1993; 58:53254-97, 55305-17.
9. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 1995; 26:1166-70.
10. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275:1893-96.
11. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Willett WC. Dietary folate, vitamin B6, vitamin B12 intake and risk of CHD among a large population of men. Abstract. Circulation 1996; 93:625.
12. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359-64.
13. Voutilainen S, Lakka TA. Low serum folate concentrations are associated with an excess incidence of acute coronary events: The Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr 2000; 54:424.
14. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT, Kuopio Ischemic Heart Disease Risk Factor Study. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001; 103:2674-80.
15. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, Whelton PK. Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey. Stroke 2002; 33:1183-88.
16. Maxwell CJ, Hogan DB, Ebly EM. Serum folate levels and subsequent adverse cerebrovascular outcomes in elderly persons. Dement Geriatr Cogn Disord 2002; 13:225-34.
17. de Bree A, Verschuren WM, Blom HJ, Nadeau M, Trijbels FJ, Kromhout D. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: A prospective study. Atherosclerosis 2003; 166:369-77.
18. Voutilainen S, Virtanen JK, Rissanen TH, Alfthan G, Laukkanen J, Nyyssonen K, Mursu J, et al. Serum folate and homocysteine and the incidence of acute coronary events: The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2004; 80:317-23.
19. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke2004;35:169-74.
20. Van Guelpen B, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson TK, Weinehall L, Witthoft C, Palmqvist R, Winkvist A. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: A prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke 2005; 36:1426-31.
21. Virtanen JK, Voutilainen S, Happonen P, Alfthan G, Kaikkonen J, Mursu J, Rissanen TH, et al. Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil 2005; 12:369-75.
22. Drogan D, Klipstein-Grobusch K, Dierkes J, Weikert C, Boeing H. Dietary intake of folate equivalents and risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition (EPIC)--Potsdam study. Public Health Nutr 2006; 9:465-71.
23. Weikert C, Dierkes J, Hoffmann K, Berger K, Drogan D, Klipstein-Grobusch K, Spranger J, Mohlig M, Luley C, Boeing H. B vitamin plasma levels and the risk of ischemic stroke and transient ischemic attack in a German cohort. Stroke 2007; 38:2912-18.
24. Ishihara J, Iso H, Inoue M, Iwasaki M, Okada K, Kita Y, Kokubo Y, Okayama A, Tsugane S, JPHC Study Group. Intake of folate, vitamin B6 and vitamin B12 and the risk of CHD: The Japan Public Health Center-Based Prospective Study Cohort I. J Am Coll Nutr 2008; 27:127-36.
25. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15:136-43.
26. Zeitlin A, Frishman WH, Chang CJ. The association of vitamin B 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: The Bronx aging study. Am J Ther 1997; 4:275-81.
27. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98:204-10.
28. Giles WH, Kittner SJ, Croft JB, Anda RF, Casper ML, Ford ES. Serum folate and risk for coronary heart disease: Results from a cohort of US adults. Ann Epidemiol 1998; 8:490-96.
29. Hung J, Beilby JP, Knuiman MW, Divitini M. Folate and vitamin B-12 and risk of fatal cardiovascular disease: Cohort study from Busselton, Western Australia. BMJ 2003; 326:131.
30. Al-Delaimy WK, Rexrode KM, Hu FB, Albert CM, Stampfer MJ, Willett WC, Manson JE. Folate intake and risk of stroke among women. Stroke 2004; 35:1259-63.
31. Dalmeijer GW, Olthof MR, Verhoef P, Bots ML, van der Schouw YT. Prospective study on dietary intakes of folate, betaine, and choline and cardiovascular disease risk in women. Eur J Clin Nutr 2008; 62(3):386-94.
32. Vanuzzo D, Pilotto L, Lombardi R, Lazzerini G, Carluccio M, Diviacco S, Quadrifoglio F, et al. Both vitamin B6 and total homocysteine plasma levels predict long-term athero-thrombotic events in healthy subjects. Eur Heart J 2007; 28:484-91.
33. Stampfer MJ, Rimm EB. Folate and cardiovascular disease. Why we need a trial now. JAMA 1996; 275:1929-30.
34. Baker F, Picton D, Blackwood S, Hunt J, Eskine M, Oyas M, Ashby M, Anjana S, Brown MJ, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: An outcome trial. Abstract. Circulation 2002; 106:3642.
35. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-75.
36. Bpnaa KH, Njplstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med2006; 354:1578-88.
37. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, et al.Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med2006; 354:1567-77.
38. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008; 299:2027-36.
39. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 2007; 298:1163-70.
40. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008; 300:795-804.
41. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15:420-26.
42. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart study: A randomized controlled trial. JAMA 2002; 288:973-79.
43. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: Results of the Goes extension study. Heart 2005; 91:1213-14.
44. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, et al.Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. JAm Coll Cardiol 2006; 47:1108-16.
45. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption: Folic acid (folacin), final rule. Fed Reg 1996; 8797-807.
46. Health Canada. Regulations amending the food and drug regulations: Schedule No. 1066 (flour fortification). Canada Gazette Part II 1998; 132.
47. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med1999; 340:1449-54.
48. Pfeiffer CM, Osterloh JD, Kennedy-Stephenson J, Picciano MF, Yetley EA, Rader JI, Johnson CL. Trends in circulating concentrations of total homocysteine among US adolescents and adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys. Clin Chem 2008; 54:801-13.
49. B-Vitamin Treatment Trialists’ Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. Am Heart J 2006; 151:282-87.
50. Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU.FOL.OM3 Study: A secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials 2008; 9:35.
51. SEARCH Study Collaborative Group, Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 2007; 154:815-23.e6.
52. Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J, FAVORIT Investigators. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J 2006; 152:448 e1-7.
53. Dusitanond P, Eikelboom JW, Hankey GJ, Thom J, Gilmore G, Loh K, Yi Q, Klijn CJ, Langton P, van Bockxmeer FM, Baker R, Jamrozik K. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: A randomized substudy of the VITATOPS trial. Stroke 2005; 36:144-46.
54. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: Rationale and design of an international, large, simple, randomised trial of homocysteinelowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2002; 13:120-26.
55. Willett W. Nutritional Epidemiology, 2nd ed. New York: Oxford University Press, 1998.
56. Barak AJ, Beckenhauer HC, Hidiroglou N, Camilo ME, Selhub J, Tuma DJ. The relationship of ethanol feeding to the methyl folate trap. Alcohol 1993; 10:495-97.
57. Shaw S, Jayatilleke E, Herbert V, Colman N. Cleavage of folates during ethanol metabolism. Role of acetaldehyde/xanthine oxidase-generated superoxide. Biochem J1989; 257:277-80.
58. Hidiroglou N, Camilo ME, Beckenhauer HC, Tuma DJ, Barak AJ, Nixon PF, Selhub J. Effect of chronic alcohol ingestion on hepatic folate distribution in the rat. Biochem Pharmacol 1994; 47:1561-66.
59. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits. BMJ 1996; 312:731-36.
60. Mukamal KJ, Jensen MK, Grpnbaek M, Stampfer MJ, Manson JE, Pischon T, Rimm EB. Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation 2005; 112:1406-13.
61. Jiang R, Hu FB, Giovannucci EL, Rimm EB, Stampfer MJ, Spiegelman D, Rosner BA, Willett WC. Joint association of alcohol and folate intake with risk of major chronic disease in women. Am J Epidemiol 2003; 158:760-71.
62. Morrison HI, Ellison LF, Schaubel D, Wigle DT. Relationship of dietary folate and vitamin B6 with coronary heart disease in women. JAMA 1998; 280:417-18; author reply 418-19.
63. Food and Nutrition Board and Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline—A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients. Washington, DC: The National Academies Press, 2000.
64. Davey Smith G, Ebrahim S. “Mendelian randomization”: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol2003; 32:1-22.
65. Ebrahim S, Davey Smith G. Mendelian randomization: Can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008; 123:15-33.
66. Kanwar YS, Manaligod JR, Wong PW. Morphologic studies in a patient with homocysti-nuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. Pediatr Res 1976; 10:598-609.
67. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis. Circulation 1998; 98: 2520-26.
68. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 2000; 151:862-77.
69. Guéant-Rodriguez RM, Guéant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: A comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006; 83:701-07.
70. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofo-late reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
71. de Bree A, Verschuren WM, Bjprke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, Blom HJ. Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 2003; 77:687-93.
72. Ashfield-Watt PA, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, Burr ML, Lewis MJ, Powers HJ, McDowell IF. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002; 76:180-86.
73. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002; 288:2023-31.
74. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C^T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331:1053.
75. Larsson SC, Mannisto S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Folate, vitamin B6, vitamin B12, and methionine intakes and risk of stroke subtypes in male smokers. Am J Epidemiol 2008; 167:954-61.
76. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JMImprovement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006; 113:1335-43.
77. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr 2003; 133:2863-67.
78. Forman JP, Rimm EB, Stampfer MJ, Curhan GC. Folate intake and the risk of incident hypertension among US women. JAMA 2005; 293:320-29.
79. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurology 2002; 59:529-36.
80. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: Evidence from a cumulative meta-analysis. Stroke 2005; 36:1581-87.
81. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: Evidence on a causal link from mendelian randomisation. Lancet 2005; 365:224-32.
82. Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: A meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med 2007; 4:e131.
83. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: Thirty-two genes involving approximately 18 000 cases and 58 000 controls. Arch Neurol 2004; 61:1652-61.
84. Moats C, Rimm EB. Vitamin intake and risk of coronary disease: Observation versus intervention. Curr AtherosclerRep 2007; 9:508-14.
85. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007; 369:1876-82.
86. Spence JD. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial. Clin Chem Lab Med 2007; 45:1582-85.
87. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, Selhub J, et al.Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006; 136:189-94.
88. Chiuve SE, Giovannucci EL, Hankinson SE, Hunter DJ, Stampfer MJ, Willett WC, Rimm EB. Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine. Am J Clin Nutr 2005; 82:155-62.
89. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007; 85:193-200.
90. Bentley TG, Weinstein MC, Willett WC, Kuntz KM. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr 2008; 1-13.